Switch to:

Alexion Pharmaceuticals Return-on-Tangible-Equity

: -146.21% (As of Jun. 2020)
View and export this data going back to 1996. Start your Free Trial

Return-on-Tangible-Equity is calculated as Net Income attributable to Common Stockholders divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alexion Pharmaceuticals's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2020 was $-4,272 Mil. Alexion Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Jun. 2020 was $2,922 Mil. Therefore, Alexion Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2020 was -146.21%.

NAS:ALXN' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.33   Med: 27.51   Max: 142.41
Current: 34.42

13.33
142.41

During the past 13 years, Alexion Pharmaceuticals's highest Return-on-Tangible-Equity was 142.41%. The lowest was 13.33%. And the median was 27.51%.

NAS:ALXN's Return-on-Tangible-Equity is ranked higher than
95% of the 1071 Companies
in the Biotechnology industry.

( Industry Median: -50.36 vs. NAS:ALXN: 34.42 )

Alexion Pharmaceuticals Return-on-Tangible-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Alexion Pharmaceuticals Annual Data
Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.96 Negative Tangible Equity Negative Tangible Equity 40.01 142.41

Alexion Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Return-on-Tangible-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.91 105.13 147.86 82.94 -146.21

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Alexion Pharmaceuticals Return-on-Tangible-Equity Distribution

* The bar in red indicates where Alexion Pharmaceuticals's Return-on-Tangible-Equity falls into.



Alexion Pharmaceuticals Return-on-Tangible-Equity Calculation

Alexion Pharmaceuticals's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2019 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2019 )  (A: Dec. 2018 )(A: Dec. 2019 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2019 )  (A: Dec. 2018 )(A: Dec. 2019 )
=2404.3/( (486.6+2890.1 )/ 2 )
=2404.3/1688.35
=142.41 %

Alexion Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2020 is calculated as

Return-on-Tangible-Equity=Net Income attributable to Common Stockholders/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2020 )  (Q: Mar. 2020 )(Q: Jun. 2020 )
=Net Income attributable to Common Stockholders/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2020 )  (Q: Mar. 2020 )(Q: Jun. 2020 )
=-4272.4/( (2488.1+3355.9)/ 2 )
=-4272.4/2922
=-146.21 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

In the calculation of annual Return-on-Tangible-Equity, the net income attributable to common stockholders of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2020) net income attributable to common stockholders data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Alexion Pharmaceuticals  (NAS:ALXN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Alexion Pharmaceuticals Return-on-Tangible-Equity Related Terms


Alexion Pharmaceuticals Return-on-Tangible-Equity Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)